Vicasinabin

Vicasinabin
Identifiers
	IUPAC name (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol;
CAS Number	1433361-02-4;
PubChem CID	86296048;
ChemSpider	115010437;
UNII	QJ8UO6C05M;
KEGG	D12511;
ChEMBL	ChEMBL5314566;
Chemical and physical data
Formula	C15H22N10O
Molar mass	358.410 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)C1=NC2=C(C(=N1)N3CC[C@@H](C3)O)N=NN2CC4=NN=NN4C;
	InChI InChI=1S/C15H22N10O/c1-15(2,3)14-16-12(24-6-5-9(26)7-24)11-13(17-14)25(21-19-11)8-10-18-20-22-23(10)4/h9,26H,5-8H2,1-4H3/t9-/m0/s1; Key:MAYZWDRUFKUGGP-VIFPVBQESA-N;

Vicasinabin (RG7774) is a potent cannabinoid agonist which is highly selective for the CB₂ receptor subtype. It was developed by Roche as a potential agent for the treatment of diabetic retinopathy. It reached Phase II human clinical trials but was discontinued for lack of efficacy, although it continues to be used for scientific research.^[1]^[2]

[1]

[2]

Identifiers

IUPAC name (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol
CAS Number	1433361-02-4
PubChem CID	86296048
ChemSpider	115010437
UNII	QJ8UO6C05M
KEGG	D12511
ChEMBL	ChEMBL5314566
Chemical and physical data
Formula	C₁₅H₂₂N₁₀O
Molar mass	358.410 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)(C)C1=NC2=C(C(=N1)N3CC[C@@H](C3)O)N=NN2CC4=NN=NN4C
InChI InChI=1S/C15H22N10O/c1-15(2,3)14-16-12(24-6-5-9(26)7-24)11-13(17-14)25(21-19-11)8-10-18-20-22-23(10)4/h9,26H,5-8H2,1-4H3/t9-/m0/s1 Key:MAYZWDRUFKUGGP-VIFPVBQESA-N

Related Articles